Bu Hong , Fan Ying , Fan Zhaoqing , Hu Xichun , Li Man , Li Qiao , Liao Ning , Luo Ting , Nie Jianyun , Pan Yueyin , Qi Xiaowei , Shao Zhimin , Song Guohong , Sun Tao , Teng Yue-e , Tong Zhongsheng , Wang Jiayu , Wang Shusen , Wang Xue , Wang Yongsheng , Zhao Jiuda
{"title":"低her2乳腺癌临床诊断与治疗共识(2022版)","authors":"Bu Hong , Fan Ying , Fan Zhaoqing , Hu Xichun , Li Man , Li Qiao , Liao Ning , Luo Ting , Nie Jianyun , Pan Yueyin , Qi Xiaowei , Shao Zhimin , Song Guohong , Sun Tao , Teng Yue-e , Tong Zhongsheng , Wang Jiayu , Wang Shusen , Wang Xue , Wang Yongsheng , Zhao Jiuda","doi":"10.1016/j.jncc.2023.09.002","DOIUrl":null,"url":null,"abstract":"<div><p>Treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2; HER2-low) has drawn much attention in recent years. With the proven therapeutic effect of trastuzumab deruxtecan (T-DXd) in patients with HER2-low (immunohistochemistry [IHC] 1+, or IHC2+/in situ hybridization [ISH]-) breast cancer, HER2-low may become a new subtype of targeted therapy for breast cancer. The expert committee formulated this consensus based on the current clinical studies and clinical medication experience. The current consensus is the collaborative work of an interdisciplinary working group, including experts in the fields of pathology and oncology. The purpose of this consensus was to guide the clinical diagnosis and treatment of HER2-low breast cancer, thereby prolonging the overall survival of patients.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 4","pages":"Pages 266-272"},"PeriodicalIF":7.6000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005423000650/pdfft?md5=59cb1c043eec46b7b4255c534bcabea6&pid=1-s2.0-S2667005423000650-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)\",\"authors\":\"Bu Hong , Fan Ying , Fan Zhaoqing , Hu Xichun , Li Man , Li Qiao , Liao Ning , Luo Ting , Nie Jianyun , Pan Yueyin , Qi Xiaowei , Shao Zhimin , Song Guohong , Sun Tao , Teng Yue-e , Tong Zhongsheng , Wang Jiayu , Wang Shusen , Wang Xue , Wang Yongsheng , Zhao Jiuda\",\"doi\":\"10.1016/j.jncc.2023.09.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2; HER2-low) has drawn much attention in recent years. With the proven therapeutic effect of trastuzumab deruxtecan (T-DXd) in patients with HER2-low (immunohistochemistry [IHC] 1+, or IHC2+/in situ hybridization [ISH]-) breast cancer, HER2-low may become a new subtype of targeted therapy for breast cancer. The expert committee formulated this consensus based on the current clinical studies and clinical medication experience. The current consensus is the collaborative work of an interdisciplinary working group, including experts in the fields of pathology and oncology. The purpose of this consensus was to guide the clinical diagnosis and treatment of HER2-low breast cancer, thereby prolonging the overall survival of patients.</p></div>\",\"PeriodicalId\":73987,\"journal\":{\"name\":\"Journal of the National Cancer Center\",\"volume\":\"3 4\",\"pages\":\"Pages 266-272\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2667005423000650/pdfft?md5=59cb1c043eec46b7b4255c534bcabea6&pid=1-s2.0-S2667005423000650-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the National Cancer Center\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667005423000650\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Center","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667005423000650","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)
Treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2; HER2-low) has drawn much attention in recent years. With the proven therapeutic effect of trastuzumab deruxtecan (T-DXd) in patients with HER2-low (immunohistochemistry [IHC] 1+, or IHC2+/in situ hybridization [ISH]-) breast cancer, HER2-low may become a new subtype of targeted therapy for breast cancer. The expert committee formulated this consensus based on the current clinical studies and clinical medication experience. The current consensus is the collaborative work of an interdisciplinary working group, including experts in the fields of pathology and oncology. The purpose of this consensus was to guide the clinical diagnosis and treatment of HER2-low breast cancer, thereby prolonging the overall survival of patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
